Sermorelin vs. Ipamorelin: Different Receptors, Same Regulatory Status

How sermorelin and ipamorelin actually differ

They reach the same endpoint by different routes, and this part of the comparison is genuine.

Sermorelin is a GHRH analog

Sermorelin is a synthetic fragment of growth-hormone-releasing hormone — the first 29 amino acids, the shortest portion that retains activity. It binds the GHRH receptor on the pituitary, which is the same receptor the body's own GHRH uses. It is, in effect, a copy of the natural signal.

Ipamorelin is a growth hormone secretagogue

Ipamorelin is not a GHRH analog. It acts on the ghrelin receptor, a separate pathway that also drives growth hormone release. Ghrelin is better known as a hunger hormone, and this receptor is the target of the growth-hormone-releasing peptide class rather than the GHRH class.

Both routes end in the pituitary releasing the body's own growth hormone, which then raises IGF-1. Neither supplies growth hormone directly — that is injected HGH, a different thing again.

The practical consequence: because they act on separate receptors, they are not substitutes in a pharmacological sense, and that is the basis for the combination protocols discussed below.

Is ipamorelin really more selective?

This is the single most repeated claim in this comparison: that ipamorelin is selective, raising growth hormone without meaningfully raising cortisol or prolactin, and that this makes it cleaner than older growth-hormone-releasing peptides.

The claim originates in preclinical pharmacology, where ipamorelin was characterised against earlier GHRPs that did stimulate other pituitary hormones. That is a real distinction in that context.

What is worth knowing is what the claim does not rest on. It describes receptor behaviour observed in laboratory and animal models, not outcomes measured in an adult treatment population over time. There is no approved adult label reporting ipamorelin's hormonal effects, because there is no approved adult indication. Selectivity in a preclinical model is a reasonable thing to note. It is not the same as a demonstrated safety advantage in patients, and most pages present it as though it were.

Should sermorelin be taken with ipamorelin?

This is the most common follow-up question, and the honest answer is that the combination has not been established in an approved regimen.

The pharmacological argument for combining them is real on paper: because they act on different receptors, stimulating both is not the same as doubling one. That is the reasoning behind the widely sold GHRH-plus-secretagogue stacks.

What does not exist is a registration trial establishing that the combination is safe or effective in adults, or an approved dosing regimen for it. Every stack protocol circulating online is a compounding and prescribing convention, not a studied schedule.

Since both raise IGF-1, combining them makes monitoring more important rather than less. That is a conversation for a prescriber with your labs in hand.

Which one is right for you?

Most pages answer this with a personality quiz. Pick sermorelin if you want a gentler natural pulse, pick ipamorelin if you want something cleaner. That framing assumes the choice is between two established treatments, and it is not.

Neither has an approved adult indication. Both are compounded. Any adult use of either is off-label by definition, which means the real question is not which one, it is whether either has a defensible role for you at all.

At NovaGenix that starts with baseline labs including IGF-1 and glucose, a physician reviewing whether there is a clinical reason to consider a growth-hormone-raising therapy, and an honest answer when there is not. Sometimes the answer is a different therapy entirely. Sometimes it is none.

If the peptide actually under discussion is tesamorelin rather than ipamorelin, the regulatory picture is different in a way that matters: tesamorelin vs. sermorelin covers the one compound in this group that does hold a current FDA approval for adults.